Gabriela Escalante

Dr. Gabriela Escalante

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2020 in Vaccines
Verified
Journal Article
Open access
PDF file
GEGabriela Escalante
Gabriela Escalante
JFJoslyn Foley
Joslyn Foley
LMLorraine Z. Mutsvunguma
Lorraine Z. Mutsvunguma
EREsther Rodriguez
Esther Rodriguez
DMDavid H. Mulama
David H. Mulama
JOJavier Ogembo
Javier Ogembo
Primary infection with Epstein-Barr virus (EBV) is associated with acute infectious mononucleosis, whereas persistent infection is associated with chronic diseases such as autoimmune diseases and various types of cancer. Indeed, approximately 2% of all new cancer cases occurring annually worldwide are EBV-associated. Currently, there is no licensed EBV prophylactic vaccine. Selection of appropriate viral protein subunits is critical for development of an effective vaccine. Although the major EBV surface glycoprotein gp350/220 (gp350) has been proposed as an important prophylactic vaccine target, attempts to develop a potent vaccine based on gp350 alone have shown limited success in the clinic. We provide data showing that five EBV glycoproteins (gp350, gB, gp42, gH, and gL) involved in viral entry and infection can successfully be incorporated on the surface of EBV-like particles (EBV-LPs). These EBV-LPs, when administered together with aluminum hydroxide and monophosphoryl lipid A as adjuvants to New Zealand white rabbits, elicited EBV glycoprotein-specific antibodies capable of neutralizing viral infection in vitro in both B cells and epithelial cells, better than soluble gp350 ectodomain. Our findings suggest that a pentavalent EBV-LP formulation might be an ideal candidate for development as a safe and immunogenic EBV vaccine.

1 December 2017 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
Kenneth PollardKenneth Pollard
Kenneth Pollard
GEGabriela Escalante
Gabriela Escalante
HHHua Huang
Hua Huang
KHKatarina M. Haraldsson
Katarina M. Haraldsson
PHPer Hultman
Per Hultman
DKDwight H. Kono
Dwight H. Kono
Type I IFN and nucleic acid–sensing TLRs are both strongly implicated in the pathogenesis of lupus, with most patients expressing IFN-induced genes in peripheral blood cells and with TLRs promoting type I IFNs and autoreactive B cells. About a third of systemic lupus erythematosus patients, however, lack the IFN signature, suggesting the possibility of type I IFN–independent mechanisms. In this study, we examined the role of type I IFN and TLR trafficking and signaling in xenobiotic systemic mercury-induced autoimmunity (HgIA). Strikingly, autoantibody production in HgIA was not dependent on the type I IFN receptor even in NZB mice that require type I IFN signaling for spontaneous disease, but was dependent on the endosomal TLR transporter UNC93B1 and the endosomal proton transporter, solute carrier family 15, member 4. HgIA also required the adaptor protein-3 complex, which transports TLRs from the early endosome to the late endolysosomal compartments. Examination of TLR signaling pathways implicated the canonical NF-κB pathway and the proinflammatory cytokine IL-6 in autoantibody production, but not IFN regulatory factor 7. These findings identify HgIA as a novel type I IFN–independent model of systemic autoimmunity and implicate TLR-mediated NF-κB proinflammatory signaling from the late endocytic pathway compartments in autoantibody generation.

13 June 2024 in Journal of Virology
Verified
Journal Article
Closed access
Murali MunirajuMurali Muniraju
Murali Muniraju
LMLorraine Z. Mutsvunguma
Lorraine Z. Mutsvunguma
IRIvana G. Reidel
Ivana G. Reidel
GEGabriela Escalante
Gabriela Escalante
SCSimeon Cua
Simeon Cua
JOJavier Ogembo
Javier Ogembo
Kaposi sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus-8, is the causal agent of Kaposi sarcoma, a cancer that appears as tumors on the skin or mucosal surfaces, as well as primary effusion lymphoma and KSHV-associated multicentric Castleman disease, which are B-cell lymphoproliferative disorders. Effective prophylactic and therapeutic strategies against KSHV infection and its associated diseases are needed. To develop these strategies, it is crucial to identify and target viral glycoproteins involved in KSHV infection of host cells. Multiple KSHV glycoproteins expressed on the viral envelope are thought to play a pivotal role in viral infection, but the infection mechanisms involving these glycoproteins remain largely unknown. We investigated the role of two KSHV envelope glycoproteins, KSHV complement control protein (KCP) and K8.1, in viral infection in various cell types in vitro and in vivo . Using our newly generated anti-KCP antibodies, previously characterized anti-K8.1 antibodies, and recombinant mutant KSHV viruses lacking KCP, K8.1, or both, we demonstrated the presence of KCP and K8.1 on the surface of both virions and KSHV-infected cells. We showed that KSHV lacking KCP and/or K8.1 remained infectious in KSHV-susceptible cell lines, including epithelial, endothelial, and fibroblast, when compared to wild-type recombinant KSHV. We also provide the first evidence that KSHV lacking K8.1 or both KCP and K8.1 can infect human B cells in vivo in a humanized mouse model. Thus, these results suggest that neither KCP nor K8.1 is required for KSHV infection of various host cell types and that these glycoproteins do not determine KSHV cell tropism. IMPORTANCE: Kaposi sarcoma-associated herpesvirus (KSHV) is an oncogenic human gamma-herpesvirus associated with the endothelial malignancy Kaposi sarcoma and the lymphoproliferative disorders primary effusion lymphoma and multicentric Castleman disease. Determining how KSHV glycoproteins such as complement control protein (KCP) and K8.1 contribute to the establishment, persistence, and transmission of viral infection will be key for developing effective anti-viral vaccines and therapies to prevent and treat KSHV infection and KSHV-associated diseases. Using newly generated anti-KCP antibodies, previously characterized anti-K8.1 antibodies, and recombinant mutant KSHV viruses lacking KCP and/or K8.1, we show that KCP and K8.1 can be found on the surface of both virions and KSHV-infected cells. Furthermore, we show that KSHV lacking KCP and/or K8.1 remains infectious to diverse cell types susceptible to KSHV in vitro and to human B cells in vivo in a humanized mouse model, thus providing evidence that these viral glycoproteins are not required for KSHV infection.

11 June 2026 in Journal of Virology
Verified
Journal Article
Open access
EKErasmus N. Kotey
Erasmus N. Kotey
PSPreeti Sharma
Preeti Sharma
EREsther Rodriguez
Esther Rodriguez
JGJean Patrick Gonzalez-Dahua
Jean Patrick Gonzalez-Dahua
BTBrenda A. Tello
Brenda A. Tello
JOJavier Ogembo
Javier Ogembo
Epstein-Barr virus (EBV) is implicated in multiple epithelial and lymphoid malignancies worldwide; however, no licensed prophylactic vaccine exists, partly due to the lack of an adequate preclinical animal model to test candidate vaccines. Rhesus lymphocryptovirus (rhLCV) faithfully recapitulates EBV infection, persistence, and pathogenesis in rhesus macaques, offering an invaluable surrogate model. While recombinant EBV expressing enhanced green fluorescent protein (eGFP) enables swift identification of infected cells in vitro and ex vivo , an analogous tool for rhLCV has been lacking. Here, employing en passant recombination technology, we engineered a recombinant rhLCV expressing eGFP (rhLCV.eGFP) from an rhLCV bacterial artificial chromosome derived from the B-lymphoblastoid rhesus macaque cell line LCL 8664. Whole-genome sequencing confirmed sequence integrity, and functional assays demonstrated infectivity in peripheral blood mononuclear cells (PBMCs) from multiple primate species and EBV-susceptible human cell lines, and transformation competence in rhesus macaque PBMCs. To define the role of gp350/220 (gp350) in viral entry, we generated a glycoprotein gp350-deficient mutant (rhLCV.eGFPΔgp350), verified by Sanger sequencing and immunoblotting with a novel anti-gp350 monoclonal antibody (4A6). This mutant exhibited markedly reduced infectivity in rhLCV.eGFP-susceptible human B and epithelial cell lines, underscoring gp350 as a key determinant of B cell tropism, analogous to EBV gp350. Our successful engineering of rhLCV.eGFP provides a powerful platform for visualizing infection, dissecting viral entry mechanisms and cellular tropism, and advancing rhLCV as a surrogate EBV model for vaccine design, defining correlates of protection, studies of latency and reactivation, and preclinical testing of candidate antivirals and immunotherapies. IMPORTANCE: Epstein-Barr virus (EBV) infection is associated with various epithelial and lymphoid diseases. The absence of a suitable animal study model for EBV infection has hindered mechanistic studies of pathogenesis and preclinical testing of vaccines and EBV‑targeted therapies. Rhesus lymphocryptovirus (rhLCV), an EBV homolog, accurately recapitulates EBV infection and pathogenesis in rhesus macaques, offering a promising EBV surrogate model. In this study, we engineered a stable recombinant rhLCV expressing enhanced green fluorescent protein (eGFP), rhLCV.eGFP, for easy identification of infected or transformed cells in vitro and ex vivo . Further illustrating the utility of this platform, we also generated a gp350-deficient mutant rhLCV.eGFP and demonstrated markedly reduced infectivity in otherwise susceptible B and epithelial cells, confirming the EBV gp350-homologous role of rhLCV gp350 in viral entry. Thus, rhLCV.eGFP will serve as an invaluable resource for studying EBV biology and advancing the development of EBV prophylactic and therapeutic strategies using the rhLCV surrogate model.

17 October 2024 in Viruses
Verified
Journal Article
Open access
PDF file
SCSimeon Cua
Simeon Cua
BTBrenda Alejandra Tello
Brenda Alejandra Tello
MFMafalda de Arrábida Farelo
Mafalda de Arrábida Farelo
EREsther Rodriguez
Esther Rodriguez
GEGabriela Escalante
Gabriela Escalante
IRIvana Gabriela Reidel
Ivana Gabriela Reidel
Modified vaccinia Ankara (MVA) virus is a widely used vaccine platform, making accurate titration essential for vaccination studies. However, the current plaque forming unit (PFU) assay, the standard for MVA titration, is prone to observer bias and other limitations that affect accuracy and precision. To address these challenges, we developed a new flow cytometry-based quantification method using a highly specific monoclonal antibody (mAb) for the detection of MVA-infected cells, as a more accurate titration assay. Through previous work, we serendipitously identified three MVA-specific hybridoma antibody clones, which we characterized through ELISA, immunoblot, and flow cytometry, confirming their specificity for MVA. Sequencing confirmed that each antibody was monoclonal, and mass spectrometry results revealed that all mAbs target the MVA cell surface binding protein (CSBP, MVA105L). We next optimized the titration protocol using the most effective mAb, 33C7 by refining culture conditions and staining protocols to enhance sensitivity and minimize background. Our optimized method demonstrated superior sensitivity, reliability, and reduced processing time when compared with the traditional PFU assay, establishing it as a more accurate and efficient approach for MVA titration.

10 September 2026 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
WMWebster Musonda
Webster Musonda
GEGabriela Escalante
Gabriela Escalante
YLYu Liang
Yu Liang
RBRichard Bardin
Richard Bardin
ABAnne Barasa
Anne Barasa
JOJavier Ogembo
Javier Ogembo